These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12455406)

  • 1. Rational drug design of DNA oligonucleotides as HIV inhibitors.
    Jing N; Xu X
    Curr Drug Targets Infect Disord; 2001 Aug; 1(2):79-90. PubMed ID: 12455406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing G-quartet oligonucleotides as novel anti-HIV agents: focus on anti-HIV drug design.
    Jing N
    Expert Opin Investig Drugs; 2000 Aug; 9(8):1777-85. PubMed ID: 11060776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and development of integrase inhibitors as anti-HIV agents.
    Gupta SP; Nagappa AN
    Curr Med Chem; 2003 Sep; 10(18):1779-94. PubMed ID: 12871104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligonucleotides as inhibitors of human immunodeficiency virus.
    Field AK
    Curr Opin Mol Ther; 1999 Jun; 1(3):323-31. PubMed ID: 11713797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors. A basis for anti-HIV drug design.
    Jing N; De Clercq E; Rando RF; Pallansch L; Lackman-Smith C; Lee S; Hogan ME
    J Biol Chem; 2000 Feb; 275(5):3421-30. PubMed ID: 10652335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions.
    Maurin C; Bailly F; Cotelle P
    Curr Med Chem; 2003 Sep; 10(18):1795-810. PubMed ID: 12871105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity of inhibition of HIV-1 integrase and virus replication by G-quartet oligonucleotides.
    Jing N; Marchand C; Guan Y; Liu J; Pallansch L; Lackman-Smith C; De Clercq E; Pommier Y
    DNA Cell Biol; 2001 Aug; 20(8):499-508. PubMed ID: 11560782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potassium-dependent folding: a key to intracellular delivery of G-quartet oligonucleotides as HIV inhibitors.
    Jing N; Xiong W; Guan Y; Pallansch L; Wang S
    Biochemistry; 2002 Apr; 41(17):5397-403. PubMed ID: 11969399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In search of authentic inhibitors of HIV-1 integration.
    Debyser Z; Cherepanov P; Van Maele B; De Clercq E; Witvrouw M
    Antivir Chem Chemother; 2002 Jan; 13(1):1-15. PubMed ID: 12180645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1.
    Cherepanov P; Esté JA; Rando RF; Ojwang JO; Reekmans G; Steinfeld R; David G; De Clercq E; Debyser Z
    Mol Pharmacol; 1997 Nov; 52(5):771-80. PubMed ID: 9351967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial.
    Johnson AA; Marchand C; Pommier Y
    Curr Top Med Chem; 2004; 4(10):1059-77. PubMed ID: 15193139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HIV-1 replication by a two-strand system (FTFOs) targeted to the polypurine tract.
    Hiratou T; Tsukahara S; Miyano-Kurosaki N; Takai K; Yamamoto N; Takaku H
    FEBS Lett; 1999 Jul; 456(1):186-90. PubMed ID: 10452555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel inhibitors of HIV integrase: the discovery of potential anti-HIV therapeutic agents.
    Nair V
    Curr Pharm Des; 2003; 9(31):2553-65. PubMed ID: 14529542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug.
    Jing N; Hogan ME
    J Biol Chem; 1998 Dec; 273(52):34992-9. PubMed ID: 9857031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5.
    Bodiwala HS; Sabde S; Gupta P; Mukherjee R; Kumar R; Garg P; Bhutani KK; Mitra D; Singh IP
    Bioorg Med Chem; 2011 Feb; 19(3):1256-63. PubMed ID: 21227704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting HIV-1 integrase with strand transfer inhibitors.
    Li Y; Xuan S; Feng Y; Yan A
    Drug Discov Today; 2015 Apr; 20(4):435-49. PubMed ID: 25486307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of a new in vitro reaction substrate reproducing both U3 and U5 regions of the HIV-1 3'-ends increases the correlation between the in vitro and in vivo effects of the HIV-1 integrase inhibitors.
    Tramontano E; Onidi L; Esposito F; Badas R; La Colla P
    Biochem Pharmacol; 2004 May; 67(9):1751-61. PubMed ID: 15081874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase.
    Gu SX; Xue P; Ju XL; Zhu YY
    Bioorg Med Chem; 2016 Nov; 24(21):5007-5016. PubMed ID: 27658796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Closely related antiretroviral agents as inhibitors of two HIV-1 enzymes, ribonuclease H and integrase: "killing two birds with one stone".
    Andréola ML
    Curr Pharm Des; 2004; 10(30):3713-23. PubMed ID: 15579066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of HIV-1 replication?
    Lavigne C; Yelle J; Sauve G; Thierry AR
    AAPS PharmSci; 2002; 4(2):E9. PubMed ID: 12102618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.